SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: RMP who wrote (6162)4/15/2002 9:09:57 AM
From: Biomaven  Respond to of 52153
 
<HGSI>

The miss by .02

1. That's not a miss - that's a smaller loss than estimated.

2. More importantly, the exact amount of their loss is essentially irrelevant to the valuation of the company. They have plenty of cash and the amount of their loss is purely a reflection of how much they have elected to spend on R&D.

3. The weakness is likely because it looks like Mirostipen (not altogether unsurprisingly) failed for neutropenia. They are going to proceed with a albumin fusion version of G-CSF.

Peter



To: RMP who wrote (6162)4/15/2002 9:17:12 AM
From: orkrious  Respond to of 52153
 
The miss by .02 seems to have caused an over reaction in pre market trading.

I doubt the miss is causing the selloff. More likely it's that they are discontinuing Mirostatin <SP?>. They are starting trials of another compound to treat the same thing as Mirostatin was going to.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News